Printer Friendly

NEW HEMOPHILIA B CLOTTING FACTOR AVAILABLE TO TREAT RARE, GENETIC DISORDER

 NEW HEMOPHILIA B CLOTTING FACTOR AVAILABLE TO TREAT RARE,
 GENETIC DISORDER
 COLLEGEVILLE, Pa., Aug. 31 /PRNewswire/ -- Armour Pharmaceutical Company, a subsidiary of Rhone-Poulenc Rorer Inc. (NYSE: RPR), announced today that it received approval on Aug. 20, 1992 to market Coagulation Factor IX (Human), Mononine(TM). It is indicated for the prevention and control of bleeding in Factor IX deficiency, also known as hemophilia B or Christmas disease.
 "Mononine is the world's first monoclonal antibody (MAb) purified hemophilia B therapy," stated John A. Sedor, president of Armour Pharmaceutical Company. The availability of this product is the result of many years of research. The inclusion of Mononine in Armour's product group gives the company a line of therapies for the two major forms of hemophilia - hemophilia A and hemophilia B.
 Mononine has been granted orphan drug status, since it is indicated to treat a rare disease.
 During the development of this product, Armour supplied close to 10 million units of Mononine to more than 120 patients for clinical investigations. This included a program to provide the drug on a compassionate basis.
 There are approximately 4,000 people in the United States who have hemophilia B. Hemophilia is a genetic bleeding disorder that is usually inherited but can occur spontaneously in families that do not have a history of the disease. People with hemophilia lack a clotting factor protein in their blood, and as a result, they bleed longer because their blood cannot develop a firm clot. Internal bleeding can occur sporadically with or without an external cause.
 New Manufacturing Process
 Mononine is manufactured using a monoclonal antibody purification technology. Monoclonal antibody purification, combined with a chemical treatment step and an ultrafiltration step used in the production of Mononine, provide a high margin of safety in the elimination of blood- borne viruses, but, as with all plasma derivative products, the risk of viral infectivity cannot be totally eliminated.
 Mononine's manufacturing process uses a highly-specific monoclonal antibody to Factor IX, which effectively separates the product from other plasma proteins. The result is highly purified Factor IX concentrate, which contains non-detectable levels of Factors II, VII and X (fewer than 0.0025 units per Factor IX unit by standard coagulation assay).
 Mononine is supplied in single dose vials of approximately 250, 500 and 1,000 International Units with a double-ended needle for reconstitution, vented filter spike, winged infusion set, alcohol swabs, and directions for use. Each package contains dried Coagulation Factor IX (Human), Mononine, monoclonal antibody purified, along with Sterile Water for Injection, USP.
 Armour Pharmaceutical Company will distribute and market Mononine. The product will be available beginning in early September.
 Armour is a leading manufacturer of high-quality plasma derivatives produced by modern scientific techniques.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of human pharmaceuticals. The company reported sales of $3.8 billion in 1991 and will invest $500 million in research and development in 1992.
 -0- 8/31/92
 /CONTACT: Bob Pearson of Armour Pharmaceutical Company, 215-454-3872; or, Lee Davies of Davies & Murray, 212-750-3270, for Armour Pharmaceutical Company/
 (RPR) CO: Armour Pharmaceutical Company; Rhone-Poulenc Rorer Inc. ST: Pennsylvania IN: MTC SU:


LR-KW -- NY058 -- 5081 08/31/92 15:57 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 31, 1992
Words:534
Previous Article:FANNIE MAE REPORTS POSTED YIELDS
Next Article:CONRAD ASSUMES EXPANDED RESPONSIBILITIES AT QUAKER STATE
Topics:


Related Articles
CYTOTHERAPEUTICS AND GENETIC THERAPY TO INVESTIGATE ENCAPSULATION OF FACTOR IX TO TREAT HEMOPHILIA B
ARMOUR TO INTRODUCE SECOND RECOMBINANT FACTOR VIII PRODUCT WORLDWIDE
Genentech and Baxter Collaborate to Develop Hemophilia Gene Therapy
Cell Genesys Reports Additional Successful Preclinical Studies of Hemophilia Gene Therapy.
Cell Genesys Exclusively Licenses Technology for Liver-Directed AAV Gene Therapy From University of Washington.
Cell Genesys exclusively licenses technology for liver-directed Aav gene therapy from University of Washington.
Avigen granted broad hemophilia A gene therapy patent.
Cell Genesys obtains results from preclinical hemophilia gene therapy studies.
Targeted Genetics Presents Promising Data at Annual Meeting of the National Hemophilia Foundation.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters